Scalper1 News
Analysts were singing the praises of life-science giants Gilead Sciences (GILD) and Illumina (ILMN) Wednesday morning after both surged above Q1 estimates late Tuesday. Shares of both companies were up on the stock market today. Gilead’s $2.3 billion in sales for its new hepatitis C drug Sovaldi was called “one of the most impressive beats in biopharma history” by Piper Jaffray’s Joshua Schimmer, although he increased his price target by only a Scalper1 News
Scalper1 News